Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Non-Small-Cell Lung Cancer.

Area of Science:

• Oncology
• Health Economics
• Genomics

Background:

• Advanced non-small-cell lung cancer (aNSCLC) necessitates precise diagnostic strategies.
• Conventional testing methods may not capture the full spectrum of actionable genomic alterations.
• Comprehensive genomic profiling (CGP) offers a broader molecular assessment for targeted therapies.

Purpose of the Study:

• To evaluate the economic impact of increased CGP utilization versus conventional testing in aNSCLC patients.
• To assess the budget impact and clinical benefits of CGP from a US commercial health plan perspective.
• To determine the number of patients needed to test with CGP to achieve specific clinical outcomes.

Main Methods:

• A decision analytic model was developed to compare CGP and non-CGP testing strategies.
• The model considered both tissue-based and liquid-based sample types.
• Outcomes included direct costs, testing costs, budget impact, life-years gained, and patients needed for targeted therapy.

Main Results:

• An increase in CGP use from 20% to 30% in a hypothetical 2M-member health plan was associated with 3.11 additional life-years gained.
• The budget impact of this increase was a modest $0.01 per member per month.
• Approximately 19.6 patients needed CGP testing to gain one life-year, and 5.9 to match one patient with therapy.

Conclusions:

• Increased CGP adoption in aNSCLC patients is linked to improved survival and modest economic consequences.
• The benefits of CGP, including prolonged survival, are largely driven by enhanced access to effective, biomarker-matched treatments.
• CGP represents a valuable tool for optimizing treatment strategies and patient outcomes in advanced non-small-cell lung cancer.